Navigation Links
Cellectricon and BioFocus DPI Advance High Throughput ion Channel Drug Discovery
Date:4/27/2009

GOTHENBURG, Sweden, April 27 /PRNewswire/ -- Cellectricon, a leading provider of automated screening solutions for drug discovery, today announced its collaboration with BioFocus DPI, a contract research organization with leading expertise in ion channel screening. BioFocus DPI will utilize Cellectricon's Dynaflow(R)HT, a fully automated patch clamp (APC) system, to further increase its electrophysiology-based screening capacity, particularly for fast ligand-gated ion channels.

"Cellectricon's unique high throughput microfluidic screening platform allows us to further develop our leading platform for ion channel screening. This collaboration gives us the opportunity to increase the throughput we provide for customers as well as the number of ion channel subtypes we can screen in an electrophysiology-based format," said Dr. Kate Hilyard, VP Biological Sciences, BioFocus DPI.

"Cellectricon is very pleased to provide BioFocus DPI with this state-of-the-art enabling technology that enhances their ion channel drug discovery offering," said Jonas Ohlsson, CEO at Cellectricon. "BioFocus DPI is a leading service provider in this field, so it is natural that we collaborate on this new high throughput ion channel screening system. We are delighted to join forces with BioFocus DPI to bring this next generation APC system - with unmatched throughput and data quality at a competitive cost - to the market."

About Dynaflow(R)HT System

The Dynaflow(R)HT microfluidic ion channel screening platform is the world's first APC technology enabling high throughput screening of all kinds of ion channels - voltage gated or ligand gated. Fully automated, the Dynaflow(R)HT has a throughput exceeding all existing APC systems - at a very competitive running cost. Rapid compound exchange enables highly complex perfusion protocols, gives superior data quality, and reduces compound usage. The new Dynaflow(R)H
'/>"/>

SOURCE Cellectricon AB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Share Issue Gives Cellectricon SEK 89 Million to Continue its Rapid Market Expansion
2. Cellectricon and AstraZeneca - Partners in New High Throughput Ion Channel Drug Discovery Technology
3. Cellectricon Receives Milestone Order for Cellaxess(R)HT, the Worlds First High Throughput RNAi Screening System
4. Cellectricon Partners With The Automation Partnership - Bringing Next Generation Ion Channel Screening System to Market.
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. KGI Names Kerry Howell Vice President for Advancement
7. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
8. Advanced Cell Technology Announces Proposed Financing
9. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
10. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... HILL, N.C. , Dec. 22, 2014 /PRNewswire/ ... today announced that it has signed a letter ... company that has developed and patented a nanotechnology-based ... medical diagnostics products that enable rapid on-site collection ... alcohol use/abuse and health issues in an immediate, ...
(Date:12/22/2014)... MISSION VIEJO, Calif. , Dec. 22, 2014 /PRNewswire/ ... announce that CoPatient, an online medical bill review and ... newest offering in the FREE WellCard Savings discount health ... a medical bill that was more than they expected ... help members reduce health care costs, WellCard Savings is ...
(Date:12/22/2014)... Illinois (PRWEB) December 22, 2014 ITRA ... tenants and occupiers of commercial real estate, has further ... new offices in Perth and Brisbane, Western Australia, reports ... of directors. , ITRA Global / ACORPP (Australian ... totally independent consultancy company providing property services to a ...
(Date:12/19/2014)... OR and Hershey, PA (PRWEB) December 19, 2014 ... Pink: BJCT), a leading developer and manufacturer of ... entered into an agreement with Immunomic Therapeutics, Inc. ... Biojector®-2000 needle-free injection device with its LAMP™ vaccine ... an option for an exclusive Worldwide license to ...
Breaking Biology Technology:ALNE Announces Intention To Acquire BioTechPharma 2WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... , July 13 MacroGenics, Inc. today announced ... clinical study evaluating MGAWN1, a humanized monoclonal antibody, for ... infection due to West Nile Virus (WNV). MacroGenics, ... treat autoimmune disorders, cancer and infectious diseases, was awarded ...
... PCT ... , ... July 13, 2009 -- Progenitor Cell Therapy, LLC (PCT) today announced the recent appointment ... of Manufacturing Operations, Daryl is responsible for managing and supervising the day-to-day conduct of ...
... a network of tiny sensors as small as dewdrops called ... Scattered outdoors on rocks, fence posts and doorways, or ... a completely new and cost-effective system for safeguarding and securing ... Tel Aviv University Faculty of Engineering team drew upon the ...
Cached Biology Technology:MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus 2MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus 3MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus 4Progenitor Cell Therapy Appoints VP of Manufacturing Operations 2Progenitor Cell Therapy Appoints VP of Manufacturing Operations 3Intruder alert: Tel Aviv University's 'Smart Dew' will find you! 2
(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... 9, 2014  Wake Forest Baptist Medical Center today announced ... School of Medicine. Funding for this $50 million capital ... will be publicly launched next summer. ... former 60 series R.J. Reynolds Tobacco Company complex, adjacent ... begin immediately with plans to be ready to welcome ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... backdrop of some of the world,s most sophisticated biological research ... to his colleagues in Congress: immediately upon their return from ... reverse a recent Federal court decision that has brought embryonic ... Rep. Israel was seconded in his plea by Dr. ...
... Westminster, Colo. (August 27, 2010) Although having a ... factor for cardiovascular disease, researchers are only beginning to ... the development of the disease. Now, a study of ... Prevention Study (KEEPS), suggests that as BMI increases, so ...
... Rare but devastating, eye cancer can strike anyone at ... half of all patients partially blind. But a new ... University of Colorado School of Medicine, may change all that. ... eye can block up to 55 percent of harmful radiation, ...
Cached Biology News:Congressman, CSHL president urge quick action to reverse judicial embryonic stem cell research ban 2Congressman, CSHL president urge quick action to reverse judicial embryonic stem cell research ban 3Body mass index and thrombogenic factors in newly menopausal women 2Body mass index and thrombogenic factors in newly menopausal women 3Researcher finds revolutionary way to treat eye cancer 2
Goat polyclonal to SPFH2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: EDEPLETATKEN, corresponding to C terminal amino acids 328-339 of Human SPFH2 Entrez Gene ID: 11...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
alpha/beta-Tubulin Antibody Ship: Hot Store: -20 C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Biology Products: